GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (NAS:VRCA) » Definitions » Operating Margin %

Verrica Pharmaceuticals (Verrica Pharmaceuticals) Operating Margin % : -1,036.17% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Verrica Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-20.60 Mil. Verrica Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $1.99 Mil. Therefore, Verrica Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was -1,036.17%.

The historical rank and industry rank for Verrica Pharmaceuticals's Operating Margin % or its related term are showing as below:

VRCA' s Operating Margin % Range Over the Past 10 Years
Min: -1233.84   Med: -257.57   Max: -235.78
Current: -1233.82


VRCA's Operating Margin % is ranked worse than
75.44% of 1026 companies
in the Biotechnology industry
Industry Median: -177.195 vs VRCA: -1233.82

Verrica Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Verrica Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-20.60 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-63.22 Mil.


Verrica Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Verrica Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Operating Margin % Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial - - -257.57 -235.78 -1,233.84

Verrica Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9,133.82 -19,159.46 -6,382.42 -819.92 -1,036.17

Competitive Comparison of Verrica Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Verrica Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verrica Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Verrica Pharmaceuticals's Operating Margin % falls into.



Verrica Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Verrica Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-63.222 / 5.124
=-1,233.84 %

Verrica Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-20.599 / 1.988
=-1,036.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verrica Pharmaceuticals  (NAS:VRCA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Verrica Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Verrica Pharmaceuticals (Verrica Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.
Executives
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ted White director, officer: President and CEO C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Terry Kohler officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER PA 19380
Christopher G. Hayes officer: General Counsel C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Joe Bonaccorso officer: Chief Commercial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Gary Goldenberg director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
A Brian Davis officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Craig Ballaron director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Lawrence Eichenfield director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Diem Nguyen director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Matt Davidson 10 percent owner C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Linda Palczuk officer: Chief Operating Officer 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Chris Degnan officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380

Verrica Pharmaceuticals (Verrica Pharmaceuticals) Headlines

From GuruFocus

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-09-2023